Search Results - Guillermo Garcia-Manero
- Showing 1 - 4 results of 4
-
1
-
2
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy by Suravi Raychaudhuri, Megan Othus, Mary-Elizabeth M. Percival, Guillermo Garcia-Manero, Frederick R. Appelbaum, Harry P. Erba, Jacob S. Appelbaum
Published 2025-08-01
Article -
3
PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes by Alexandre Bazinet, Alex Bataller, Guillermo Montalban-Bravo, Kelly Chien, Koji Sasaki, Wei Ying Jen, Mahesh Swaminathan, Tapan Kadia, Courtney DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Hagop Kantarjian
Published 2025-07-01
Article -
4
Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML by David A. Sallman, Rami S. Komrokji, Amy E. Dezern, Marie Sebert, Guillermo Garcia‐Manero, Ramy Rahmé, Eric S. Winer, Jacqueline Lehmann‐Che, Gail J. Roboz, Isabelle Madelaine, Mikkael A. Sekeres, Pierre Peterlin, Onyee Chan, Odile Beyne‐Rauzy, Andrew Kuykendall, Christian Recher, Amy McLemore, Aspasia Stamatoullas, Ling Zhang, Lise Willems, Qianxing Mo, Emmanuel Raffoux, Lisa Nardelli, Céline Berthon, Najla H. Al Ali, Bruno Quesnel, Eric Padron, Hagop M. Kantarjian, Alan F. List, Lionel Ades, Jeffrey E. Lancet, Pierre Fenaux, Thomas Cluzeau
Published 2025-07-01
Article